Sar­to­rius to ac­quire French man­u­fac­tur­er for $2.6B+ in cell and gene ther­a­py play

The Ger­man life sci­ence group Sar­to­rius will be pick­ing up French con­tract man­u­fac­tur­er Poly­plus for the price of €2.4 bil­lion, or $2.6 bil­lion.

On Fri­day, Sar­to­rius an­nounced the ac­qui­si­tion through its French sub­group, Sar­to­rius Ste­d­im Biotech, which will be ac­quir­ing Poly­plus from pri­vate in­vestors Archimed and WP GG Hold­ings IV. Poly­plus has 270 em­ploy­ees and pro­duces ma­te­ri­als and com­po­nents that go in­to mak­ing vi­ral vec­tors that are used in cell and gene ther­a­pies. This in­cludes DNA/RNA reagents as well as plas­mid DNA. Poly­plus has lo­ca­tions in France, Bel­gium, Chi­na and the US.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN